Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Pharming Group N.V. PHAR: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing nearly 7% over the last 60 days.
Pharming Group N.V. Sponsored ADR Price and Consensus
Pharming Group N.V. Sponsored ADR price-consensus-chart | Pharming Group N.V. Sponsored ADR Quote
Roku, Inc. ROKU: This operator of a TV streaming platform has seen the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days.
Roku, Inc. Price and Consensus
Roku, Inc. price-consensus-chart | Roku, Inc. Quote
ProKidney Corp. PROK: This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.
ProKidney Corp. Price and Consensus
ProKidney Corp. price-consensus-chart | ProKidney Corp. Quote
MAG Silver Corp. MAG: This precious metal company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.6% over the last 60 days.
MAG Silver Corporation Price and Consensus
MAG Silver Corporation price-consensus-chart | MAG Silver Corporation Quote
Kimbell Royalty Partners, LP KRP: This oil and gas mineral and royalty company has seen the Zacks Consensus Estimate for its current year earnings increasing 83.3% over the last 60 days.
Kimbell Royalty Price and Consensus
Kimbell Royalty price-consensus-chart | Kimbell Royalty Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MAG Silver Corporation (MAG): Free Stock Analysis Report Roku, Inc. (ROKU): Free Stock Analysis Report Kimbell Royalty (KRP): Free Stock Analysis Report Pharming Group N.V. Sponsored ADR (PHAR): Free Stock Analysis Report ProKidney Corp. (PROK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research